Beam Therapeutics Inc. (BEAM) stock
BEAMNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/304% below fair value
$22.83−1.20 (-4.99%)
Close on Nov 13, 2026Market cap $2.36BP/E –Yield –
Beam Therapeutics cash
Cash and short-term investments held at the end of each period.
Beam Therapeutics's cash was $1.20B at Jun 30, 2026. For fiscal 2025 it was $1.20B, up 41.1% from the year before. The highest annual figure on record is $1.20B in fiscal 2023.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.20B | +41.1% |
| FY2024 | Dec 31, 2024 | $850.70M | -29.1% |
| FY2023 | Dec 31, 2023 | $1.20B | +9.1% |
| FY2022 | Dec 31, 2022 | $1.10B | +13.9% |
| FY2021 | Dec 31, 2021 | $965.60M | +222.2% |
| FY2020 | Dec 31, 2020 | $299.70M | +492.8% |
| FY2019 | Dec 31, 2019 | $50.55M | -65.8% |
| FY2018 | Dec 31, 2018 | $147.94M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $1.20B | 0.0% |
| Q1 FY2026 | Mar 31, 2026 | $1.20B | 0.0% |
| Q4 FY2025 | Dec 31, 2025 | $1.20B | +41.1% |
| Q3 FY2025 | Sep 30, 2025 | $1.10B | +18.8% |
| Q2 FY2025 | Jun 30, 2025 | $1.20B | +20.0% |
| Q1 FY2025 | Mar 31, 2025 | $1.20B | +9.1% |
| Q4 FY2024 | Dec 31, 2024 | $850.70M | -29.1% |
| Q3 FY2024 | Sep 30, 2024 | $925.80M | -7.4% |
| Q2 FY2024 | Jun 30, 2024 | $1.00B | -9.1% |
| Q1 FY2024 | Mar 31, 2024 | $1.10B | 0.0% |
| Q4 FY2023 | Dec 31, 2023 | $1.20B | +9.1% |
| Q3 FY2023 | Sep 30, 2023 | $1.00B | -9.1% |
| Q2 FY2023 | Jun 30, 2023 | $1.10B | -8.3% |
| Q1 FY2023 | Mar 31, 2023 | $1.10B | -8.3% |
| Q4 FY2022 | Dec 31, 2022 | $1.10B | +13.9% |
| Q3 FY2022 | Sep 30, 2022 | $1.10B | +17.8% |
| Q2 FY2022 | Jun 30, 2022 | $1.20B | +95.0% |
| Q1 FY2022 | Mar 31, 2022 | $1.20B | +138.3% |
| Q4 FY2021 | Dec 31, 2021 | $965.60M | +222.2% |
| Q3 FY2021 | Sep 30, 2021 | $933.40M | +361.6% |
| Q2 FY2021 | Jun 30, 2021 | $615.30M | +169.9% |
| Q1 FY2021 | Mar 31, 2021 | $503.50M | +98.7% |
| Q4 FY2020 | Dec 31, 2020 | $299.70M | +492.8% |
| Q3 FY2020 | Sep 30, 2020 | $202.20M | +435.4% |
| Q2 FY2020 | Jun 30, 2020 | $228.00M | +502.3% |
| Q1 FY2020 | Mar 31, 2020 | $253.40M | +62.3% |
| Q4 FY2019 | Dec 31, 2019 | $50.55M | -65.8% |
| Q3 FY2019 | Sep 30, 2019 | $37.76M | – |
| Q2 FY2019 | Jun 30, 2019 | $37.85M | – |
| Q1 FY2019 | Mar 31, 2019 | $156.14M | – |
| Q4 FY2018 | Dec 31, 2018 | $147.94M | – |
See a number that looks wrong?